AMLOGENYX Trademark

Trademark Overview


On Wednesday, September 11, 2024, a trademark application was filed for AMLOGENYX with the United States Patent and Trademark Office. The USPTO has given the AMLOGENYX trademark a serial number of 98745222. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, October 3, 2025. This trademark is owned by Amlogenyx Inc.. The AMLOGENYX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases and disorders, neurological diseases and disorders, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; new product design services in the field of gene therapy; product development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of neurological and genetic diseases and disorders; med...
amlogenyx

General Information


Serial Number98745222
Word MarkAMLOGENYX
Filing DateWednesday, September 11, 2024
Status730 - FIRST EXTENSION - GRANTED
Status DateFriday, October 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 15, 2025

Trademark Statements


Goods and ServicesPharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases and disorders, neurological diseases and disorders, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; new product design services in the field of gene therapy; product development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of neurological and genetic diseases and disorders; medical and scientific research information in the field of neurological and genetic diseases and disorders; providing medical research and scientific research information in the field of neurological and genetic diseases and disorders; providing medical research and scientific research information in the field of gene therapies

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, September 11, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmlogenyx Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Party NameAmlogenyx Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Trademark Events


Event DateEvent Description
Wednesday, September 11, 2024NEW APPLICATION ENTERED
Wednesday, March 12, 2025ASSIGNED TO EXAMINER
Friday, March 14, 2025NON-FINAL ACTION E-MAILED
Friday, January 24, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 14, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 14, 2025NON-FINAL ACTION WRITTEN
Wednesday, March 19, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 19, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 21, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 15, 2025PUBLISHED FOR OPPOSITION
Wednesday, March 19, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 9, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 15, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 10, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, October 3, 2025SOU TEAS EXTENSION RECEIVED
Friday, October 3, 2025SOU EXTENSION 1 FILED
Saturday, October 4, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 3, 2025SOU EXTENSION 1 GRANTED